Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3913]

Challenges in global cancer control

Prof Mary Gospodarowicz - University Health Network, Toronto, Canada

Challenges in global cancer control ( Prof Mary Gospodarowicz - University Health Network, Toronto, Canada )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Cutting-edge cancer care at the Miami Cancer Institute

Dr Miguel Villalona - Miami Cancer Institute, Miami, USA

Cutting-edge cancer care at the Miami Cancer Institute ( Dr Miguel Villalona - Miami Cancer Institute, Miami, USA )

Use of maintenance therapy following ASCT and real world treatment patterns in...

Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold

Use of maintenance therapy following ASCT and real world treatment patterns in multiple myeloma ( Dr Evangelos Terpos, Prof Michele Cavo, Dr Eloísa Riva, Dr Fredrik Schjesvold )

Myeloma highlights from EHA 2019

Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain

Myeloma highlights from EHA 2019 ( Prof Maria-Victoria Mateos - University of Salamanca, Salamanca, Spain )

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Comment: Pregnancy outcomes in patients with chronic myeloid leukaemia ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and...

Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands

Comment: Fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities ( Prof Anton Hagenbeek - University of Amsterdam, Amsterdam, The Netherlands )

AlloHCT conditioning intensity in AML in complete remission with residual...

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda...

AlloHCT conditioning intensity in AML in complete remission with residual disease ( Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA )

ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in...

Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy

$ASCEND: Acalabrutinib versus rituximab with idelalisib or bendamustine in relapsed or refractory CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )$

Inhibition of NADK strongly inhibits T-ALL cells from growing

Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK

Inhibition of NADK strongly inhibits T-ALL cells from growing ( Dr Etienne De Braekeleer - Wellcome Sanger Institute, Cambridge, UK )

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable...

Dr Mark Roschewski - National Cancer Institute, Bethesda, USA

Novel immunotherapy 5F9 plus rituximab well tolerated with rapid and durable responses in R/R DLBCL and indolent lymphoma ( Dr Mark Roschewski - National Cancer Institute, Bethesda, USA )

Venetoclax with bortezomib and dexamethasone shows good response but higher...

Dr Shaji Kumar - Mayo Clinic, Rochester, USA

Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in RRMM ( Dr Shaji Kumar - Mayo Clinic, Rochester, USA )

More from ecancer